Neonatal biochemical screening for disease

Clinica Chimica Acta

Volumn 315, Issue 1-2, 2002, Pages 99-110

  Clague, Alan ^a   Thomas, Andrew ^a  

^a QUEENSLAND HEALTH   (Australia)

Author keywords

Adrenal hyperplasia; Aminoacidurias; Biotinidase; Congenital hypothyroidism; Cystic fibrosis; Dried blood spots; Duchenne muscular dystrophy; Glactosemia; Neonatal screening; Phenylketonuria

Indexed keywords

BIOTINIDASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; PHENYLALANINE;

ACIDEMIA; AMINOACIDEMIA; AUXOTROPHY; BIOTINIDASE DEFICIENCY; CONGENITAL ADRENAL HYPERPLASIA; CONGENITAL HYPOTHYROIDISM; COST BENEFIT ANALYSIS; CYSTIC FIBROSIS; DIAGNOSTIC ACCURACY; DUCHENNE MUSCULAR DYSTROPHY; ENZYME DEFICIENCY; ETHICS; FLUOROMETRY; GALACTOSEMIA; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOGLOBINOPATHY; HUMAN; IMMUNOASSAY; MASS SPECTROMETRY; NEWBORN SCREENING; PHENYLKETONURIA; PRIORITY JOURNAL; REVIEW; SPECTROPHOTOMETRY; TANDEM MASS SPECTROMETRY;

ADRENAL HYPERPLASIA, CONGENITAL; CONGENITAL HYPOTHYROIDISM; COST-BENEFIT ANALYSIS; CYSTIC FIBROSIS; ETHICS, MEDICAL; GALACTOSEMIAS; HEMOGLOBINOPATHIES; HUMANS; HYPOTHYROIDISM; INFANT, NEWBORN; MENTAL RETARDATION; NEONATAL SCREENING; PHENYLKETONURIAS; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY;

BACTERIA (MICROORGANISMS);

EID: 0036133045     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(01)00716-1     Document Type: Review

References (95)

1. Influence of phenylalanine intake on phenylketonuria
2. The origin of newborn screening
3. Massachusetts metabolic disorders screening program: 1. Technics and results of urine screening
4. Successful laboratory screening for congenital hypothyroidism
5. Neonatal screening for cystic fibrosis, using immunoreactive trypsin assay in dried blood spots
6. Neonatal screening for congenital adrenal hyperplasia using 17-hydroxyprogesterone assay in filter paper blood spots
7. Liver disease in alpha-1 antitrypsin deficiency detected by screening of 200,000 infants
8. Application of electrospray tandem mass spectrometry to neonatal screening
9. Issues in newborn screening
10. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry
11. Comparative column chromatographic estimations of phenylalanine in plasma, whole blood native and paper dried capillary blood in healthy children and adults, and patients with hyperphenylalaninaemia
12. Phenylalanine: Application of a simple HPLC technique to its measurement in dried blood spots
13. Some sources of error in thyroxine screening in neonates by radioimmunoassay of whole blood spotted on blotter paper
14. Quality evaluation of newborn screening programs
15. The effect of lot to lot variability in filter paper on the quantitation of thyroxine, thyroid stimulating hormone and phenylalanine in dried blood spot samples
16. Neonatal screening using dried blood spots on to filter paper: Methodological factors which contribute to imprecision. Proceedings of the 6th international neonatal screening symposium
17. Presentation of the first European working standard for phenylalanine determination in dried blood spots
18. Validation of accuracy based amino acid reference materials in dried-blood spots by tandem mass spectrometry for newborn screening assays
19. Quality assurance and standardisation: Summary of the satellite meeting, Turku, Finland, 11-12 June 1999
20. Neonatal screening: Ethical aspects
21. Experience with screening newborns for Duchenne muscular dystrophy in Wales
22. Guidelines for the retention, storage, and use of residual dried blood spot samples after newborn screening analysis: Statement of the council of regional networks for genetic services
23. Tandem mass spectrometry screening: Proving effectiveness
24. 1-antitrypsin deficiency
25. Evaluating newborn screening programs based on dried blood spots: Future challenges
26. Why "underpowered" tests are not necessarily unethical
27. Population newborn screening for inherited metabolic disease: Current UK perspectives
28. Secondary analysis of economic data: A review of cost-benefit studies of neonatal screening for phenylketonuria
29. Neonatal hypothyroidism: Treatment and outcome
30. Antenatal and neonatal hemoglobinopathy screening in the UK: Review and economic analysis
31. Hyperphenylalaninaemia: Phenylalanine hydroxylase deficiency
32. Maternal phenylketonuria (PKU) - A review
33. Neuropsychological follow-up in neonatal screening: Issues, methods and findings
34. Fluorometric method for phenylalanine microplate assay adapted for phenylketonuria screening
35. Application of tandem mass spectrometry (MS/MS) to neonatal screening for phenylketonuria (PKU) in a UK laboratory
36. Epidemiology of congenital hypothyroidism
37. Screening for congenital hypothyroidism used as an indicator of the degree of iodine deficiency and of its control
38. Transient neonatal hypothyroidism detected by newborn screening program
39. Screening for congenital hypothyroidism with specimen collection at two time periods: Results of the North West Regional Screening Program
40. Incidence of congenital hypothyroidism: Retrospective study of neonatal laboratory screening versus clinical symptoms as indicators leading to diagnosis
41. Neonatal screening for congenital hypothyroidism by measurement of plasma thyroxine and thyroid stimulating hormone
42. Thyroxine binding globulin deficiency detected by newborn screening
43. Congenital hypothyroidism
44. Long-term neuropsychological sequelae of early-treated congenital hypothyroidism: Effects in adolescence
45. Neonatal Screening for inborn errors of metabolism: Cost, yield and outcome
46. Cystic fibrosis
47. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth
48. Neonatal screening for cystic fibrosis: Present and future
49. Screening for cystic fibrosis by testing meconium for albumin
50. Screening for cystic fibrosis
51. Galactosemia
52. A simple spot screening test for galasctosemia
53. Galactose and galactose-1-phosphate spot test for galactosemia screening
54. Diet does not ensure normal development in galactosemia
55. Principles and performance: Assessing the evidence
56. Congenital adrenal hyperplasia
57. Congenital adrenal hyperplasia in Sweden 1969-1986. Prevalence, symptoms and age at diagnosis
58. Improved precision of newborn screening for congenital adrenal hyperplasia using weight adjusted criteria for 17-hydroxyprogesterone levels
59. Should we screen for congenital adrenal hyperplasia? A review of 117 cases
60. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden
61. Newborn screening with tandem mass spectrometry: 12 Months' experience in NSW Australia
62. Laboratory integration and utilization of tandem mass spectrometry in neonatal screening: A model for clinical mass spectrometry in the next millenium
63. Two years of routine newborn screening by tandem mass spectrometry (MSMS) in New South Wales, Australia
64. The mutational spectrum in the MCAD gene of newborns identified by prospective tandem MS screening for "diagnostic" acyl-carnitines in bloodspots differs from that observed in clinically affected patients
65. Evaluation of elevated hydroxyisovalerylcarnitine (C5-OH) in the newborn screen by tandem mass spectrometry
66. The use of automated HPLC to detect and quantitate hemoglobins
67. Capillary isoelectric focussing of hemoglobin variants in the pediatric clinical laboratory
68. Neonatal screening for sickle hemoglobinopathies in Birmingham
69. Neonatal screening for sickle disease in a metropolitan university hospital: Efficacy and problems
70. Comparison of commercial screening tests for glucose-6-phosphate dehydrogenase deficiency in the neonatal period
71. Screening for glucose-6-phosphate dehydrogenase deficiency as a preventive measure: Prevalence among 1,286,000 Greek newborn infants
72. Marked decline in favism after neonatal glucose-6-phosphate dehydrogenase screening and health education: The northern Sardinian experience
73. Neonatal screening for sickle cell disease: A cost-effectiveness analysis
74. Antenatal and neonatal hemoglobinopathy screening in the UK: Review and economic analysis
75. Biotinidase deficiency
76. Comparison of patients with complete and partial biotinidase deficiency: Biochemical studies
77. A screening method for biotinidase deficiency in newborns
78. The incidence of Duchenne muscular dystrophy in eastern Austria. The controversy regarding CK screening
79. Cost-effectiveness of neonatal screening for Duchenne muscular dystrophy - How does this compare to existing neonatal screening for metabolic disorders?
80. Impact of genetic counselling after neonatal screening for Duchenne muscular dystrophy
81. A rapid screening test for Duchenne muscular dystrophy using dried blood specimens
82. Three years' experience with neonatal screening for Duchenne/Beckeb muscular dystrophy: Gene analysis, gene expression, and phenotype prediction
83. Systematic neonatal detection of Duchenne's muscular dystrophy. Results after 10 years of experience in Lyons
84. Neonatal screening for Duchenne muscular dystrophy: A novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus
85. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model
86. Development of approaches to improve cell survival in myoblast transfer therapy
87. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease
88. Enzyme replacement therapy in fabry disease: A randomized controlled trial
89. Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy and Hurler syndrome
90. Bone marrow transplantation and gene therapy for lysosomal storage diseases
91. Evaluation of the lysosome-associated membrane protein LAMP-2 as a marker for lysosomal storage disorders
92. Rapid diagnosis of lysosomal storage disorders by tandem mass spectrometry